Kane Biotech to Release Third Quarter 2020 Financial Results on November 26 – Conference Call to Follow

Nachrichtenquelle: globenewswire
19.11.2020, 23:30  |  101   |   |   

WINNIPEG, Manitoba, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2020 financial results after market close on Thursday, November 26, 2020.

Kane Biotech management will host a conference call at 4:30 p.m. ET on Monday Nov. 30, 2020 to review the financial results and discuss business developments in the period.

Third Quarter 2020 Results Conference Call Details:
   
Date: Monday November 30, 2020
Time: 4:30 p.m. ET
Live Call: 1-877-268-9044 (Canada and the United States)
  1-706-679-2995 (International)
   
Replay: 1-404-537-3406
Conference ID: 3572374

The call will also be broadcast live and archived on the Company's website at www.kanebiotech.com under "News/Events" in the Investors section.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactive+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information, please visit www.kanebiotech.com, or contact:

Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
+1 (514) 910-6991
medwards@kanebiotech.com

Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
+1 (204) 298-2200
rdupuis@kanebiotech.com

Graham Farrell
Investor Relations

Harbor Access
+1 (416) 842 9003
Graham.Farrell@HarborAccessllc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Seite 1 von 2
Kane Biotech Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Kane Biotech to Release Third Quarter 2020 Financial Results on November 26 – Conference Call to Follow WINNIPEG, Manitoba, Nov. 19, 2020 (GLOBE NEWSWIRE) - Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products …

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel